Anaptysbio (ANAB) Payables (2016 - 2026)

Anaptysbio has reported Payables for 11 years, with the latest figure at $7.5 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 22.77% year-over-year to $7.5 million; the trailing twelve-month figure through Mar 2026 stood at $7.5 million (up 22.77% YoY), and the FY2025 full-year result was $3.9 million, down 3.27% from the prior year.
• Payables for Q1 2026 stood at $7.5 million, up from $3.9 million in the prior quarter.
• The five-year high for Payables was $7.5 million in Q1 2026, with the low at $1.6 million in Q2 2022.
• Historically, Payables has averaged $4.1 million across 5 years, with a median of $3.9 million in 2025.
• Annual changes were most pronounced in 2022 — Payables tumbled 61.32% — and 2023, when it surged 200.0%.
• Anaptysbio's Payables stood at $2.8 million in 2022, then jumped by 68.75% to $4.7 million in 2023, then dropped by 14.81% to $4.0 million in 2024, then retreated by 3.27% to $3.9 million in 2025, then surged by 94.19% to $7.5 million in 2026.
• The last three Payables figures came in at $7.5 million (Q1 2026), $3.9 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.